Roche’s Xofluza reduces flu transmission in Phase 3 study
According to the company, the results are the first time an antiviral drug has reduced transmission of a respiratory virus in ...
Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses
Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza from an infected person to ...
The Pharma Letter3d
Roche touts positive Phase III results with Xofluza
Roche today released positive top-line results of the Phase III CENTERSTONE study of Xofluza (baloxavir marboxil), an ...
Roche's Xofluza Reduces Influenza Transmission In Phase III Study
Xofluza (baloxavir marboxil), an antiviral medication, achieved its primary endpoint in the phase III CENTERSTONE ...
Roche's Antiviral Drug Reduces Transmission Of Influenza Viruses, Late-Stage Study Shows
Roche's phase 3 CENTERSTONE study shows Xofluza (baloxavir marboxil) significantly reduces influenza transmission in ...
Pharmabiz2d
Roche announces phase III CENTERSTONE study of Xofluza significantly reduces the transmission of influenza viruses
Roche announces phase III CENTERSTONE study of Xofluza significantly reduces the transmission of influenza viruses: Basel Friday, September 20, 2024, 09:00 Hrs [IST] Roche announc ...
Business Wire3d
Positive Phase III Results Show Xofluza Significantly Reduces the Transmission of Influenza Viruses
--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results of the Phase III CENTERSTONE study of Xofluza ® (baloxavir ...
Morningstar3d
Positive Phase III Results Show Xofluza Significantly Reduces the Transmission of Influenza Viruses
Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza from an infected person to household members – – This is the first time that any antiviral used in ...
Stockhouse3d
Positive Phase III Results Show Xofluza Significantly Reduces the Transmission of Influenza Viruses
The study met its primary endpoint, demonstrating that a single, oral dose of Xofluza taken by people infected with influenza significantly reduced the likelihood of others in their household ...
Roche Antiviral Drug Reduces Transmission in Late-stage Study
Results from a late-stage study on RHHBY's Xofluza show that the drug reduces the transmission of influenza from an infected ...
Joplin Globe3d
Positive Phase III Results Show Xofluza Significantly Reduces the Transmission of Influenza Viruses
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results of the Phase III CENTERSTONE study of Xofluza ® (baloxavir marboxil), an antiviral ...